Liraglutide
Also called Saxenda, Victoza.
Liraglutide has FDA-approved products for specific uses. This page cites 1 source, and the strongest evidence comes from human trials.
- Status
- FDA-approved product exists
- Form
- Pen injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 1
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
Daily subcutaneous liraglutide produced greater weight loss than placebo at 56 weeks in adults without type 2 diabetes who had obesity, or overweight with hypertension or dyslipidemia.
Limits: SCALE Obesity and Prediabetes randomized 3,731 adults and provided lifestyle counseling to both groups. Nausea and diarrhea were common. This trial does not establish the effects of a different product, dose, or population.
Regulatory status
United States
As of November 6, 2026, Saxenda is FDA-approved for long-term weight reduction with diet and activity in label-defined populations with obesity or adult overweight with a weight-related condition.
United States
As of November 6, 2026, Victoza is FDA-approved for type 2 diabetes glucose control from age 10 and cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease.